Working... Menu
Trial record 29 of 46 for:    disulfiram

Clinical Efficacy of Disulfiram in LAAM-Maintained Cocaine Abusers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00580827
Recruitment Status : Completed
First Posted : December 27, 2007
Last Update Posted : December 27, 2007
National Institute on Drug Abuse (NIDA)
Information provided by:
Yale University

Brief Summary:
This 18-week, randomized, double blind clinical trial provided treatment for 160 cocaine-dependent opioid addicts, aged 18-65 years. Participants were stabilized on LAAM maintenance during the first 4 weeks and cocaine use was assessed; participants were then stratified by level of cocaine use and randomly assigned to receive one of the following: placebo disulfiram (0 mg/day), disulfiram at 62.5 mg/day, disulfiram at 125 mg/day, or disulfiram at 250 mg/day. During induction onto LAAM, participants were administered increasing doses of LAAM plus placebo disulfiram on a thrice-weekly basis until maintenance doses of LAAM are attained. At the beginning of week 5, participants received LAAM plus disulfiram or placebo disulfiram according to their randomized assignments, and were maintained on these agents through week 16. At the end of the study, participants underwent detoxification from LAAM and active/placebo medication over a 4- to 6-week period. All participants received weekly 1-hour psychotherapy (Cognitive Behavioral Treatment) with experienced clinicians specifically trained to deliver the therapy and who received ongoing supervision. The primary outcomes were retention and reduction in opioid and cocaine use, as assessed by self-report and confirmed by thrice-weekly urinalyses. Secondary outcomes included reductions in other illicit drug and alcohol use, as well as improvements in psychosocial functioning.

Condition or disease Intervention/treatment Phase
Cocaine-Related Disorder Opiate Dependence Drug: Placebo Drug: Disulfiram Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 126 participants
Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Clinical Efficacy of Disulfiram in LAAM-Maintained Cocaine Abusers
Study Start Date : September 2003
Actual Primary Completion Date : March 2004

Resource links provided by the National Library of Medicine

Drug Information available for: Disulfiram

Arm Intervention/treatment
Placebo Comparator: placebo disulfiram
placebo disulfiram (0 mg/day)
Drug: Placebo
Matched placebo.

Experimental: disulfiram 62.5
disulfiram at 62.5 mg/day
Drug: Disulfiram
disulfiram at 62.5 mg/day for 12 weeks.

Experimental: disulfiram 125
disulfiram at 125 mg/day
Drug: Disulfiram
Disulfiram at 125 mg/day for 12 weeks.

Experimental: disulfiram 250
disulfiram at 250 mg/day
Drug: Disulfiram
disulfiram at 250 mg/day for 12 weeks.

Primary Outcome Measures :
  1. Reductions in cocaine use as measured by urine toxicology and self-report [ Time Frame: 14 weeks ]

Secondary Outcome Measures :
  1. Predictors of treatment efficacy using DBH genotyping for disulfiram will be tested. [ Time Frame: 14 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Between the ages of 18-65 years.
  • Are not currently enrolled in treatment.
  • Participants must demonstrate opioid dependence, as evidenced by documentation of prior opioid agonist maintenance and/or have signs of withdrawal upon administration of naloxone (<0.8 mg, i.m.), and an opioid-positive urine screen.
  • Participants also must be current users of cocaine with self-reported use of > 7 gm during the preceding 12 months, self-reported use of > 1 time/week in at least one month preceding study entry, and cocaine-positive urine screen.
  • Participants must fulfill DSM-IV criteria for opioid and cocaine dependence.

Exclusion Criteria:

  • current diagnosis of other drug or alcohol physical dependence (other than opiates, cocaine or tobacco)
  • significant medical conditions such as abnormal liver function (with laboratory findings greater than three times normal).
  • active hepatitis; hypertension; a current cardiac condition or high risk of cardiovascular disease; seizure disorders; or another significant underlying medical condition which would contraindicate disulfiram or LAAM treatment.
  • meets DSM-IV psychiatric classifications for schizophrenia, bipolar disorder, or other psychotic disorders; exhibiting current suicidality or homicidality; current use of a prescribed psychotropic medication that cannot be discontinued.
  • pregnancy.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00580827

Layout table for location information
United States, Connecticut
West Haven VA
West Haven, Connecticut, United States, 06516
Sponsors and Collaborators
Yale University
National Institute on Drug Abuse (NIDA)
Layout table for investigator information
Principal Investigator: James Poling, Ph.D. Yale University

Layout table for additonal information
Responsible Party: James Poling, Ph.D. / Research Scientist, Yale University Identifier: NCT00580827     History of Changes
Other Study ID Numbers: R01DA013441 ( U.S. NIH Grant/Contract )
NIDA R01 DA13441
First Posted: December 27, 2007    Key Record Dates
Last Update Posted: December 27, 2007
Last Verified: December 2007

Additional relevant MeSH terms:
Layout table for MeSH terms
Cocaine-Related Disorders
Opioid-Related Disorders
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Anesthetics, Local
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents
Vasoconstrictor Agents
Dopamine Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Dopamine Agents
Neurotransmitter Agents
Alcohol Deterrents
Acetaldehyde Dehydrogenase Inhibitors
Enzyme Inhibitors